{"title":"Prospects for the use of allosteric drugs in real-world clinical practice","authors":"I. R. Svechkareva, A. Kolbin","doi":"10.37489/2782-3784-myrwd-43","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-43","url":null,"abstract":"While the clinical validity of the use of allosteric regulation is known, scientists are working on the discovery of new methods for the development of allosteric drugs that can modulate the functions of enzymes, depending on the desired therapeutic effect, and have a broader safety profile compared with alternative drugs. Allosteric modulators are of increasing interest in medicine, some of which are already used in the clinic and some can potentially be used in real-world clinical practice. This article summarizes the current knowledge about allosteric modulation of receptors and their clinical prospects.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"47 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138950837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. S. Motrinchuk, O. A. Loginovskaya, V. P. Kolbatov
{"title":"Methods for drug safety signal detection using routinely collected observational electronic health care data: a systematic review","authors":"A. S. Motrinchuk, O. A. Loginovskaya, V. P. Kolbatov","doi":"10.37489/2782-3784-myrwd-35","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-35","url":null,"abstract":"Signal detection is a crucial step in the discovery of post-marketing adverse drug reactions. There is a growing interest in using routinely collected data to complement established spontaneous report analyses.The aim. This work aims to systematically review the methods for drug safety signal detection using routinely collected healthcare data and their performance, both in general and for specific types of drugs and outcomes.Metodology. We conducted a systematic review following the PRISMA guidelines, and registered a protocol in PROSPERO.Results. The review included 101 articles, among which there were 39 methodological works, 25 performance assessment papers, and 24 observational studies. Methods included adaptations from those used with spontaneous reports, traditional epidemiological designs, methods specific to signal detection with real-world data. More recently, implementations of machine learning have been studied in the literature. Twenty-five studies evaluated method performances, 16 of them using the area under the curve (AUC) for a range of positive and negative controls as their main measure. Despite the likelihood that performance measurement could vary by drug-event pair, only 10 studies reported performance stratified by drugs and outcomes, in a heterogeneous manner. The replicability of the performance assessment results was limited due to lack of transparency in reporting and the lack of a gold standard reference set.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115679160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Decentralized clinical trials: regulatory perspectives in Russia and the EAEU","authors":"M. Borzova, S. V. Semina","doi":"10.37489/2782-3784-myrwd-32","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-32","url":null,"abstract":"This article describes regulatory approaches to the decentralized clinical trials (in whole or in part) in international practice, as well as in the Russian Federation and the Eurasian Economic Union.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125500251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Evaluation of the potential economic effects in the increased vaccination against meningococcal infection based on real epidemiological data","authors":"S. Svetlichnaya, L. A. Elagina, L. Popovich","doi":"10.37489/2782-3784-myrwd-34","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-34","url":null,"abstract":"Meningococcal infection (MI) is one of the heaviest illnesses with specific clinical picture and outcomes. MI prophylaxis is also actual from a social-economic viewpoint. Analysis based on RWD is important and should include epidemiological, medical, regional economic parameters as well as demographic data.Aim: economic evaluation of the potential outcomes of vaccination against MI in Far East Federal District of Russia (FER) in frames of vaccination growth in children.Materials and methods: Modelling of epidemiological and economic outcomes of MI vaccination with MenACWY-D vaccine in 95% of 3-year-old children in FER. Economic model usage cost vaccination, its efficacy, morbidity after vaccine usage, and mortality with such kind of parameters comparison w/o vaccination. The economic gain of vaccination is calculated in terms of the prevented loss of life years and the monetary equivalent of the per capita domestic regional product.Results: Vaccination against MI in 100 thousand children aged 3 years will decrease morbidity by 64,5% and mortality by 75% during 8 years after vaccination. Social gain is 5,8 mln RUR due to morbidity decrease and 1,3 bln RUR due to saving lives.Conclusion: Vaccination has an economic advantage — benefit after 100 thousand children vaccination up to 4,3 times higher than cost of vaccination in FER.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116139377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Overview of FDA guidelines for patient engagement in medical product development and regulatory decision making","authors":"V. Borovskaya, A. Kasimova","doi":"10.37489/2782-3784-myrwd-31","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-31","url":null,"abstract":"About 10 years ago, the FDA launched an initiative to expand the role of patients in informing regulators and sponsors about the most serious consequences of the disease and the main treatment goals that can lead to desired medical outcomes. This initiative has grown into four guidance that aim.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126871966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drug utilization research at the individual level as the main concept of pharmacoepidemiology","authors":"S. M. Mukhina, M. I. Baranova, Y. Gomon","doi":"10.37489/2782-3784-myrwd-33","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-33","url":null,"abstract":"Pharmacoepidemiological studies are necessary to improve the system of rational use of drugs and to identify the most problematic areas. Such studies make it possible to evaluate not only quantitative indicators of consumption but also indicators such as patient adherence, frequency of cases of polypharmacy, and drug abuse.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134127412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Assessing the risks of abuse of opioids in real-world data","authors":"M. Pchelintsev","doi":"10.37489/2782-3784-myrwd-29","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-29","url":null,"abstract":"In the review, data from foreign medical publications are presented, which are dedicated to the narcogenic potential of a strong opioid. Risk assessments of drug addiction development, of its diversification into illegal trafficking for non-medical use are given. Assessment data have a comparative character with opioids. In analyzed articles, the authors used different methodological approaches to the assessment of strong opioids narcogenicity, in particular to the evaluation of the results of population-based cohort studies, to the analysis of large databases accumulating data on different drug abuse, including opioids, data on intoxication with preparations of the group, and some others. Based on the analysis of published assessment results of potential risks of strong opioids use, the author gives the evaluation of the organization of its accountability and prescription in the Russian Federation.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126921977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Role of RWD / RWE in health technology assessment","authors":"V. Borovskaya, A. Kurylev","doi":"10.37489/2782-3784-myrwd-26","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-26","url":null,"abstract":"For many reasons randomized clinical trials today can»t cope with the tasks set by modern health care, which was clearly demonstrated by the COVID-19 pandemic. This gave new impetus to the development of the RWD / RWE. It became obviously that in cases of impossibility, unethical and other reasons, new methods for obtaining high-quality evidence may be effectively used, and later can be used by decision-makers and organizations engaged in the assessment of health technologies.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128831758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Maintaining patient registries, on the basis of which regulatory authorities can make decisions regarding medicines","authors":"A. Ivanov, V. N. Semykin","doi":"10.37489/2782-3784-myrwd-30","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-30","url":null,"abstract":"The use of data and evidence from real clinical practice (RWD / RWE) is becoming more and more relevant to the healthcare system when making critical decisions in the field of drug circulation regulation, as well as making decisions on the inclusion or non-inclusion of a drug in government funding programs.This article discusses the role of clinical registries as one of the most important sources of RWD / RWE. Definitions of terminology are given, and various types of registers are described according to the type of information collected, methods of its collection, storage, and processing. It also shows the possibility of using registers in decision-making, describes the mechanisms for consolidating information from various types of registers, as well as obtaining data for analysis from other sources, shows the importance of correct collection and validation of data collected in the register.The article also briefly describes the local experience in the development, implementation, and maintenance of registers on the example of a number of disorders.It was prepared using guidelines prepared by the Office of Medical Policy of the Center for Drug Evaluation and Research in collaboration with the Center for Biological Evaluation and Research and the US Food and Drug Administration»s Center of Excellence in Oncology.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126597390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The need for types of inpatient treatment and budget forecasting for lung cancer patients with a first established diagnosis","authors":"Y. Yurkova, V. Merabishvili, E. Levchenko","doi":"10.37489/2782-3784-myrwd-28","DOIUrl":"https://doi.org/10.37489/2782-3784-myrwd-28","url":null,"abstract":"Creating a disease models based on real-world clinical data from the moment of diagnosis is an important task of the healthcare system, it allows to simulate the quantitative need for hospitalizations with various options for necessary treatment and calculate the approximate amount of necessary funding.The study aims to build a model calculating the necessary volumes of medical care and funding for inpatient treatment of patients with lung cancer.Materials and methods. Anonymized data from the territorial compulsory medical insurance fund and the Department of high-tech medical care for all cases of lung cancer and metastases of any localization (ICD-10: C34 and C77-78) for residents of St. Petersburg, who received medical care from 2011 to 2020. Data from the population cancer registry database for all lung cancer patients in St. Petersburg since 2000.Results. More than 75 % of hospitalizations occur within 1 year from the moment of diagnosis: 68 % — chemotherapeutic treatment, 17 % — surgery, 3 % — radiotherapy. In the first year, 1 patient with stages I and II has an average of 2 hospitalizations, III and IV — 3. The calculated by the model number of hospitalizations in the 2 236 lung cancer patients in 5 years is 7 108. Payment for inpatient care based on the tariffs of the federal fund of 2022 and the number of newly diagnosed lung cancer diagnoses for five years will cost the healthcare system 1.1 billion RUR, and more than 74 % of this amount is the cost of 1 year of treatment. During the 5 years, surgery will cost 145 million RUR, chemotherapy — more than 898 million RUR, and radiotherapy — 37 million RUR.Conclusion. The developed on the real-world clinical data model can be used to calculate the necessary healthcare needs and its costs.","PeriodicalId":447615,"journal":{"name":"Real-World Data & Evidence","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125248234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}